Literature DB >> 23768070

Epidemiology of myeloproliferative neoplasms in the United States.

Jyotsna Mehta1, Hongwei Wang, Sheikh Usman Iqbal, Ruben Mesa.   

Abstract

Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutical manufacturers. Therefore, we have described the incidence of MF and prevalence of MF, ET and PV in the United States between 2008 and 2010 based on data from two large health plans. The incidence of primary MF was about 1 per 100 000 per year and did not vary over the study years. The prevalence of PV (44-57 per 100 000) and ET (38-57 per 100 000) was much higher than that of MF (4-6 per 100 000) or subgroups containing MF (post-PV MF = 0.3-0.7 per 100 000; post-ET MF = 0.5-1.1 per 100 000). Additional research using other national databases and/or study designs is needed to substantiate these findings.

Entities:  

Mesh:

Year:  2013        PMID: 23768070     DOI: 10.3109/10428194.2013.813500

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  75 in total

1.  Shared-care model for complex chronic haematological malignancies.

Authors:  Verna Cheung; Nancy Siddiq; Rebecca Devlin; Caroline McNamara; Vikas Gupta
Journal:  Can Oncol Nurs J       Date:  2021-05-01

2.  Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.

Authors:  A Hanif; P N Hari; E Atallah; K-S B Carlson; M C Pasquini; L C Michaelis
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 3.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 4.  Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant.

Authors:  Michael Byrne; Bipin Savani; Michael R Savona
Journal:  Ther Adv Hematol       Date:  2018-07-16

Review 5.  Kinase signaling and targeted therapy for primary myelofibrosis.

Authors:  Qiong Yang; John D Crispino; Qiang Jeremy Wen
Journal:  Exp Hematol       Date:  2016-12-30       Impact factor: 3.084

6.  Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms.

Authors:  Jennifer Huberty; Ryan Eckert; Krisstina Gowin; Jules Mitchell; Amylou C Dueck; Brenda F Ginos; Linda Larkey; Ruben Mesa
Journal:  Haematologica       Date:  2017-06-08       Impact factor: 9.941

7.  Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.

Authors:  M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson
Journal:  J Intern Med       Date:  2020-01-11       Impact factor: 8.989

8.  Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.

Authors:  Hanneke J C M Wouters; René Mulder; Isabelle A van Zeventer; Jan Jacob Schuringa; Melanie M van der Klauw; Pim van der Harst; Arjan Diepstra; André B Mulder; Gerwin Huls
Journal:  Blood Adv       Date:  2020-12-22

9.  Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.

Authors:  Hyoung Soo Choi; Junshik Hong; Sang Mee Hwang; Ju Hyun Lee; Youngeun Ma; Sang-A Kim; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2021-07-30       Impact factor: 3.673

Review 10.  Ruxolitinib dose management as a key to long-term treatment success.

Authors:  Ruben A Mesa; Rami S Komrokji; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-08-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.